| Literature DB >> 34220369 |
Liang Geng1, Peizhao Du2, Yuan Yuan1, Liming Gao1, Yunkai Wang1, Jiming Li1, Qi Zhang1.
Abstract
BACKGROUND: Treatment of coronary intermediate lesions remains a controversy, and the role of arterial remodeling patterns determined by intravascular ultrasound in intermediate lesion is still not well known. The aim of this study was to investigate the impact of arterial remodeling of intermediate coronary lesions on long-term clinical outcomes.Entities:
Mesh:
Year: 2021 PMID: 34220369 PMCID: PMC8213497 DOI: 10.1155/2021/9915759
Source DB: PubMed Journal: J Interv Cardiol ISSN: 0896-4327 Impact factor: 2.279
Figure 1Flowchart of patient enrollment. IR, intermediate remodeling; NR, negative remodeling; PR, positive remodeling.
Figure 2Illustration of arterial remodeling patterns of intermediated lesions.
Baseline characteristics of the study group.
| IR ( | NR ( | PR ( |
| |
|---|---|---|---|---|
| Age, years | 63.68 ± 10.93 | 65.43 ± 8.94 | 62.67 ± 8.94 | 0.238 |
| Male, | 42 (58.33) | 38 (49.35) | 45 (71.43) | 0.030 |
| Hypertension, | 47 (65.28) | 54 (70.13) | 35 (55.56) | 0.196 |
| Hypercholesterolemia, | 12 (16.67) | 10 (12.99) | 9 (14.29) | 0.814 |
| Diabetes, | 23 (31.94) | 22 (28.57) | 24 (38.10) | 0.484 |
| Current smoker, | 27 (37.50) | 19 (24.68) | 27 (42.86) | 0.063 |
| Prior PCI history, | 8 (11.11) | 11 (14.29) | 7 (11.11) | 0.795 |
| Prior CABG history, | 1 (1.39) | 2 (2.60) | 1 (1.59) | 0.845 |
| Left ventricular eject fraction (%) | 62.10 ± 3.11 | 62.28 ± 2.65 | 61.66 ± 3.44 | 0.536 |
| Prior MI | 2 (2.78) | 1 (1.30) | 1 (1.59) | 0.785 |
| BMI | 24.94 ± 1.32 | 24.65 ± 1.26 | 25.19 ± 1.47 | 0.071 |
| Multivessel disease, | 49 (63.64) | 39 (54.17) | 38 (60.32) | 0.493 |
| Laboratory | ||||
| Creatinine ( | 67.17 ± 16.65 | 72.49 ± 17.48 | 76.96 ± 21.31 | 0.015 |
| LDL-C (mmol/l) | 2.72 ± 0.96 | 2.71 ± 0.93 | 2.54 ± 1.03 | 0.560 |
| TG (mmol/l) | 1.64 ± 1.13 | 1.60 ± 0.92 | 1.51 ± 0.94 | 0.786 |
| HBA1c (%) | 6.28 ± 1.04 | 6.18 ± 0.84 | 6.69 ± 1.36 | 0.044 |
| Medications at discharge | ||||
| Aspirin, | 58 (80.56) | 54 (70.13) | 46 (73.02) | 0.327 |
| Clopidogrel, | 19 (26.39) | 30 (38.96) | 23 (36.51) | 0.237 |
| Statin, | 63 (87.50) | 70 (90.91) | 54 (85.71) | 0.621 |
| | 41 (56.94) | 36 (46.75) | 34 (53.97) | 0.440 |
| ACEI/ARB, | 26 (36.11) | 28 (36.36) | 17 (26.98) | 0.426 |
| Insulin, | 3 (4.17) | 1 (1.30) | 5 (7.94) | 0.153 |
| Oral hypoglycemic agents, | 11 (15.28) | 11 (14.29) | 17 (26.98) | 0.109 |
ACEI, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; HBA1c, hemoglobin A1c; IR, intermediate remodeling; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; NR, negative remodeling; PCI, percutaneous coronary intervention; PR, positive remodeling; TG, triglyceride.
IVUS measurements.
| Remodeling of intermediate lesions |
| |||||
|---|---|---|---|---|---|---|
| IR ( | NR ( | PR ( | NR vs. IR | NR vs. PR | IR vs. PR | |
| Vessel | ||||||
| LAD, | 51 (70.8) | 55 (71.4) | 43 (68.3) | 0.94 | 0.68 | 0.75 |
| LCX, | 7 (9.7) | 9 (11.7) | 5 (7.9) | 0.7 | 0.46 | 0.72 |
| RCA, | 14 (19.4) | 13 (16.9) | 15 (23.8) | 0.69 | 0.31 | 0.54 |
| Morphological analysis | ||||||
| Soft, | 12 (16.7) | 13 (16.9) | 22 (34.9) | 0.97 | 0.01 | 0.01 |
| Fibrous, | 30 (41.67) | 24 (31.2) | 13 (20.63) | 0.18 | 0.16 | 0.01 |
| Calcified, | 2 (2.78) | 5 (6.49) | 4 (6.35) | 0.28 | 0.97 | 0.32 |
| Mixed, | 28 (38.9) | 35 (45.45) | 24 (38.1) | 0.42 | 0.38 | 0.92 |
| Attenuated plaque, | 7 (9.72) | 11 (14.29) | 20 (31.75) | 0.39 | 0.01 | <0.01 |
| Plaque rupture, | 1 (1.39) | 0 (0) | 1 (1.59) | 0.3 | 0.27 | 0.92 |
| Lesion length | 16.73 ± 6.79 | 17.00 ± 6.33 | 19.23 ± 7.56 | 0.8 | 0.05 | 0.04 |
| Remodeling index | 0.94 ± 0.04 | 0.76 ± 0.09 | 1.15 ± 0.12 | <0.01 | <0.01 | <0.01 |
| Minimal lumen site | ||||||
| EEM CSA (mm2) | 15.27 ± 4.46 | 11.54 ± 2.92 | 17.35 ± 6.20 | <0.01 | <0.01 | 0.025 |
| Lumen CSA (mm2) | 5.05 ± 1.39 | 4.16 ± 1.03 | 4.85 ± 1.76 | <0.01 | <0.01 | 0.48 |
| Area stenosis (%) | 54.61 ± 9.09 | 59.32 ± 10.15 | 51.67 ± 12.96 | <0.01 | <0.01 | 0.13 |
| Plaque burden (%) | 66.12 ± 6.82 | 63.45 ± 6.13 | 71.17 ± 6.45 | 0.01 | <0.01 | <0.01 |
| Eccentricity | 0.84 ± 0.13 | 0.79 ± 0.17 | 0.82 ± 0.16 | 0.04 | 0.18 | 0.53 |
| Reference site | ||||||
| EEM CSA at proximal reference (mm2) | 17.84 ± 5.43 | 17.03 ± 5.04 | 16.81 ± 5.93 | 0.34 | 0.82 | 0.3 |
| EEM CSA at distal reference (mm2) | 14.83 ± 4.97 | 13.36 ± 3.90 | 13.19 ± 5.17 | 0.046 | 0.84 | 0.07 |
| Lumen CSA at proximal reference (mm2) | 12.22 ± 3.68 | 11.69 ± 3.91 | 11.32 ± 4.36 | 0.4 | 0.6 | 0.2 |
| Lumen CSA at distal reference (mm2) | 10.39 ± 3.35 | 9.60 ± 2.87 | 9.59 ± 3.22 | 0.13 | 0.97 | 0.16 |
CSA, cross-sectional area; EEM, external elastic membrane; IR, intermediate remodeling; NR, negative remodeling; PR, positive remodeling.
Figure 3Morphological and quantitative IVUS measurements among lesions with different remodeling patterns. P < 0.01 vs. PR; #P < 0.01 vs. PR. EEM, external elastic membrane; IR, intermediate remodeling; MLA, minimum lumen area; NR, negative remodeling; PB, plaque burden; PR, positive remodeling.
Figure 4QFR and MLA measurements among QFR analyzable lesions with different remodeling patterns. IR, intermediate remodeling; MLA, minimum lumen area; NR, negative remodeling; PR, positive remodeling; QFR, quantitative flow ratio.
Clinical outcomes.
| Remodeling of intermediate lesions |
| |||||
|---|---|---|---|---|---|---|
| IR ( | NR ( | PR ( | NR vs. IR | NR vs. PR | IR vs. PR | |
| Cardiac death, | 0 (0) | 1 (1.3) | 0 (0) | 0.33 | 0.36 | NA |
| TVR, | 1 (1.4) | 10 (13.0) | 3 (4.8) | 0.007 | 0.095 | 0.25 |
| TVMI, | 0 (0) | 1 (1.3) | 0 (0) | 0.33 | 0.36 | NA |
| VOCE, | 1 (1.4) | 11 (14.3) | 3 (4.8) | 0.004 | 0.06 | 0.25 |
IR, intermediate remodeling; NR, negative remodeling; PR, positive remodeling; TVR, target vessel revascularization; TVMI, target vessel-related myocardial infarction; VOCE, vessel-oriented clinical events.
Figure 5Kaplan–Meier curves for VOCE. IR, intermediate remodeling; NR, negative remodeling; PR, positive remodeling; VOCE, vessel-oriented clinical events.
Independent predictors for VOCE.
| Hazard ratio | 95% CI |
| |
|---|---|---|---|
| RI < 0.88 | 4.849 | 1.542–15.251 | 0.007 |
| Previous PCI | 3.309 | 1.128–9.703 | 0.029 |
VOCE, vessel-oriented clinical events; PCI, percutaneous coronary intervention; RI, remodeling index.